Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.

[1]  D. Isenberg,et al.  An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. , 2006, Rheumatology.

[2]  G. Illei,et al.  Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. , 2002, Arthritis and rheumatism.

[3]  A. Fornoni,et al.  Outcomes in African Americans and Hispanics with lupus nephritis. , 2006, Kidney international.

[4]  M. Tonelli,et al.  Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[5]  W. Mccune,et al.  Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. , 1988, The New England journal of medicine.

[6]  S. Sacks,et al.  Prospective Registry‐Based Observational Cohort Study of the Long‐Term Risk of Malignancies in Renal Transplant Patients Treated with Mycophenolate Mofetil , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  V. D’Agati,et al.  Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  R. Falk,et al.  Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. , 1997, Kidney international.

[9]  M. Urowitz,et al.  The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study , 2007, Annals of the rheumatic diseases.

[10]  Zhihong Liu,et al.  Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. , 2002, Chinese medical journal.

[11]  T. Chan,et al.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. , 2005, Journal of the American Society of Nephrology : JASN.

[12]  M. Petri,et al.  Cyclophosphamide: new approaches for systemic lupus erythematosus , 2004, Lupus.

[13]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[14]  D. Boumpas,et al.  Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy , 1993, Annals of Internal Medicine.

[15]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[16]  T. Chan,et al.  Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis , 2000 .

[17]  Weiming Wang,et al.  Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  J. Reveille,et al.  A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. , 2007, Arthritis and rheumatism.

[19]  G. Appel,et al.  Update on the treatment of lupus nephritis. , 2006, Kidney international.

[20]  Y. Levy,et al.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. , 2004, Arthritis and rheumatism.

[21]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[22]  D. Isenberg,et al.  Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) , 2007, Lupus.

[23]  P H Plotz,et al.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.

[24]  C. Lau,et al.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. , 2000, The New England journal of medicine.

[25]  Mimi Y. Kim,et al.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. , 2005, The New England journal of medicine.

[26]  R. Moore,et al.  Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis , 2006, Arthritis research & therapy.

[27]  J. Ioannidis,et al.  Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. , 2000, Kidney international.

[28]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[29]  D. Boumpas,et al.  Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus , 2004, Lupus.

[30]  A. Steinberg,et al.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis , 1992, The Lancet.

[31]  A. Steinberg,et al.  A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. , 1974, Arthritis and rheumatism.

[32]  M. García-Carrasco,et al.  Cardiovascular risk factors and the long-term outcome of lupus nephritis. , 2001, QJM : monthly journal of the Association of Physicians.

[33]  J. Killen.  Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis. , 2006, The New England journal of medicine.

[34]  Z. Morad,et al.  Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis , 2005, Nephrology.

[35]  Y. Levy,et al.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. , 2002, Arthritis and rheumatism.

[36]  D. Roth,et al.  Sequential therapies for proliferative lupus nephritis. , 2004, The New England journal of medicine.